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Abstract 
The cyclic adenosine monophosphate (cAMP) intracellular signaling pathway mediates the 
physiological effects of several hormones and neurotransmitters, acting by the activation of G-
protein coupled receptors (GPCRs) and several downstream intracellular effectors, including the 
heterotrimeric stimulatory G-protein (Gs), the cAMP-dependent protein kinase A (PKA) and 
cAMP-specific phosphodiesterases (PDEs). Defective G protein-mediated signaling has been 
associated to an increasing number of disorders, including Albright hereditary osteodistrophy 
(AHO) and pseudohypoparathyroidism (PHP), a heterogeneous group of rare genetic metabolic 
disorders due to molecular defects at the GNAS locus. Moreover, mutations in PRKAR1A and 
PDE4D genes have been recently detected in patients with acrodysostosis (ACRDYS), showing a 
skeletal and endocrinological phenotype partially overlapping with AHO/PHP. 
Despite the high detection rate of molecular defects by currently available molecular approaches, 
about 30% of AHO/PHP patients still lack a molecular diagnosis, hence the need to screen patients 
negative for GNAS epi/genetic defects also for chromosomal regions and genes associated to 
diseases that undergo differential diagnosis with PHP. 
According to the growing knowledge on Gsα-cAMP signaling-linked disorders, we investigated our 
series of patients (n=81) with a clinical diagnosis of PHP/AHO but negative for GNAS anomalies 
for the presence of novel genetic variants at PRKAR1A and PDE4D genes. Our work allowed the 
detection of 8 novel missense variants affecting genes so far associated to ACRDYS in 9 patients. 
Our data further confirm the molecular and clinical overlap among these disorders; we present the 
data collected from a large series of patients and a brief review of the literature, in order to 
compare our findings with already published data, to look for PRKAR1A/PDE4D mutation 
spectrum, recurrent mutations and mutation hot spots, and to identify specific clinical features 
associated to ACRDYS, that deserve surveillance during follow-up. This article is protected by 
copyright. All rights reserved 
Key words (5): GNAS; AHO; PRKAR1A; PDE4D; Acrodysostosis.  
 This article is protected by copyright. All rights reserved 3 
 
Introduction 
The cyclic adenosine monophosphate (cAMP) intracellular signaling pathway mediates the 
physiological effects of several hormones and neurotransmitters, including the parathyroid 
hormone (PTH), acting by the activation of G-protein coupled receptors (GPCRs). This signaling 
cascade relies on the transient activation of the heterotrimeric stimulatory G-protein (Gs), adenylyl 
cyclase (AC) and cAMP-dependent protein kinase A (PKA), resulting in the phosphorylation of 
effectors and the generation of cellular responses. Defective G protein-mediated signaling has been 
associated to an increasing number of retinal, endocrine, metabolic, and developmental disorders. 
(1-5)
  
Inactivating mutations in the α-stimulatory subunit of the Gs protein (Gsα), encoded by the GNAS 
gene, cause Albright hereditary osteodystrophy (AHO), a syndrome with characteristic skeletal and 
developmental abnormalities (short stature, brachydactyly, subcutaneous ossifications, centripetal 
obesity, rounded facies, and mental and/or developmental deficits). Due to the tissue-specific 
imprinted nature of GNAS, patients who inherit Gsα mutations from their mother, in addition to the 
AHO phenotype, also develop resistance to various hormones (mainly PTH and TSH), a condition 
referred to as Pseudohypoparathyroidism type 1A (PHP1A, MIM103580). In contrast, paternal 
inheritance of the same defects is associated with the AHO phenotype only, also called 
Pseudopseudohypoparathyroidism (PPHP, MIM612463). 
(6-7)
 Moreover, sporadic or maternally-
inherited GNAS epigenetic defects lead to Pseudohypoparathyroidism type 1B (PHP1B, 
MIM603233), that may be also occasionally associated with signs of AHO. 
(8)
 
Despite the high detection rate of GNAS molecular defects, about 30% of patients with a clinical 
suspect of PHP/AHO still lack a confirming molecular diagnosis, hence the need to screen patients 
negative for GNAS defects also for alterations within chromosomal regions and genes associated to 
diseases clinically similar to AHO. Notably, it is sometimes difficult to distinguish between AHO 
and other phenotypically related skeletal disorders only on the basis of clinical and radiological 
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findings. 
(9)
 Mutations in genes encoding proteins crucial for cAMP-mediated signaling have been 
recently detected in a small subset of patients negative for GNAS defects, showing a phenotypic 
overlap between PHP and Acrodysostosis. 
(10-20)
 
The term Acrodysostosis (ACRDYS) describes a group of rare skeletal disorders characterized by 
severe brachydactyly, nasal and/or midfacial hypoplasia and variable 
intellectual/developmental/behavioural disabilities; resistance to multiple hormones that bind to 
GPCRs (including PTH and TSH), progressive growth failure with short stature, advanced bone 
age and obesity are frequently observed features. 
(21)
 Genetic defects affecting PRKAR1A (cAMP-
dependent protein kinase type I-α regulatory subunit) and PDE4D (cAMP-specific 
phosphodiesterase 4D), both crucial for cAMP signaling pathway, were associated to ACRDYS in 
2011 and 2012 by different research groups. 
(10-12) 
 
According to the growing knowledge on Gsα-cAMP signaling-linked disorders, we investigated 
our series of patients with a clinical diagnosis of PHP1A/AHO but negative for GNAS defects for 
the presence of novel genetic variants at PRKAR1/PDE4D genes. In particular, in the present work 
we present the data collected from 9 mutated of 81 investigated cases and a brief review of the 
literature, in order to compare our findings with already published data, to look for 
PRKAR1A/PDE4D mutation spectrum, recurrent mutations and mutation hot spots, and to identify 
poorly investigated clinical features associated to ACRDYS, that deserve surveillance during 
follow-up.  
 
Materials and Methods 
Patients 
The present series involved 28 patients with a clinical diagnosis of PHP1A (14 females and 14 
males) and 53 with apparently isolated AHO (36 females and 17 males). Within this large Italian 
series of patients, one was from Bosnia and Herzegovina. The inclusion criteria were the presence 
of at least two of AHO manifestations: brachydactyly (shortening of fourth and/or fifth 
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metacarpals), ectopic ossifications, short stature (height below the 3
rd
 percentile for chronological 
age), rounded facies (broad face, depressed nasal bridge, hypertelorism), and intellectual 
disabilities and/or behavioural problems (mild-to-moderate mental retardation, behavioral 
disorders and/or developmental disabilities). Among required AHO signs, skeletal abnormalities 
had to be present in order to be included into the study. The diagnosis of PHP1A was based upon 
the associated detection of at least PTH resistance (i.e. hypocalcemia, hyperphosphatemia and 
raised serum PTH levels). The Ellsworth-Howard test was performed only in one PRKAR1A-
mutated patient (pt PHP4), showing a blunted cAMP and phosphaturic urinary response, as 
previously described by Linglart and co-workers
(10)
. Twenty four of the patients also showed an 
elevated TSH, documented by raised serum TSH levels, absence of anti-thyroid antibodies and 
presence of normal thyroid scan. Clinical details of mutated patients and the whole investigated 
series are resumed in Table 1 and Supplemental Table 1, respectively.  
The presence of genetic/epigenetic defects affecting GNAS locus had been previously excluded in 
all samples by Sanger sequencing of Gsα coding exons 1-13 and Methylation Specific-Multiplex 
Ligand-dependent Probe Amplification (MS-MLPA) of STX16 and GNAS loci, both methods 
previously described. 
(22, 23)
  
Informed consent was obtained from all patients (or legal guardians for minors) and relatives 
included in the present study. 
 
Mutational analysis of PRKAR1A and PDE4D genes 
Genomic DNA was extracted from peripheral blood leukocytes by Nucleon BACC2 genomic DNA 
purification kit (GE Healthcare, Piscataway, NJ, USA) according to the manufacturer's instructions. 
Obtained DNA was amplified by PCR for PRKAR1A and PDE4D exons and flanking intronic 
sequences (PRKAR1A ENSG00000108946; PDE4D ENSG00000113448), using specific primers 
resumed in the Supplemental Table 2. Direct sequencing was performed with the AmpliTaq BigDye 
Terminator kit and the 3130xl Genetic Analyzer (Applied Biosystems, Foster City, CA), as 
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previously described. 
(22)
 The mutation nomenclature follows the guidelines indicated by Human 
Genome Variation Society (HGVS - available at http://www.hgvs.org/mutnomen/). Nucleotide 
numbering is based on the PRKAR1A transcript ENST00000392711/NM_002734, while for the 
PDE4D gene on the LRG sequence (available also at www.lovd.nl/PDE4D), corresponding to the 
PDE4D transcript ENST00000502484/NM_001165899. 
 
In silico analysis of novel genetic variants of PRKAR1A and PDE4D genes 
In order to predict the possible in vivo effect of novel PRKAR1A and PDE4D genetic defects 
detected in our series, we performed an extensive review of published data and an in silico analysis 
using different computer generated algorithms. 
(10-20)
 In silico analyses aren’t a substitute for 
functional studies in determining the pathogenicity of a genetic variant, but allow to evaluate the 
impact of mutations on the protein product, based on combined analysis of protein multiple 
sequence alignment and protein structural and functional attributes. In particular, we used the 
following algorithms: Polymorphism phenotyping program 2. Polyphen2 (available at 
http://genetics.bwh.harvard.edu/pph2/), Sort Intolerant From Tolerant human Protein, SIFT human 
Protein program (available at http://sift.jcvi.org/www/SIFT_enst_submit.html) and Mutation Taster 
(available at http://www.mutationtaster.org/). 
(22)
  
 
Results 
In our cohort of 81 patients with a clinical diagnosis of PHP1A or AHO but negative for GNAS 
genetic and/or epigenetic defects, in 9 patients we identified 8 novel genetic variants affecting the 
2 genes so far associated to ACRDYS: these were all missense alterations leading to changes in the 
amino acidic sequence, as reported in Table 1. In particular, we detected 4 mutations in the 
PRKAR1A coding sequence and 4 in the PDE4D gene, one of which demonstrated to co-segregate 
with the disorder in the only familial case (pts PHP1 & PHP2) (Table 1, Figure 1 & 2). Sequencing 
analysis of healthy control individuals (n=50) did not reveal any of the variants found in our cases. 
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Moreover, these genetic alterations were also absent in online databases of polymorphisms 
(dbSNP, available at http://www.ncbi.nlm.nih.gov/SNP/) and  mutations previously associated to 
Carney Complex (CNC1 – MIM160980), a multiple neoplasia syndrome characterized by cardiac, 
endocrine, cutaneous, and neural myxomatous tumors, and ACRDYS (PRKAR1A Mutation 
Database, available at http://prkar1a.nichd.nih.gov/hmdb/mutations.html; LOVD PDE4D, 
available at http://www.LOVD.nl/PDE4D).   
 
PRKAR1A genetic defects in our series 
The PRKAR1A gene encodes for the most abundantly expressed regulatory subunit of PKA, the 
type 1α regulatory subunit (RIα), that consists of a dimerization domain (DD), an inhibitory site 
(IS) and two cyclic nucleotide-binding domains (NBD-A and NBD-B). 
(3)
  
Sanger sequencing analysis of coding exons 2-11 in our patients unraveled 4 previously 
undescribed heterozygous missense variants (c.524A>G, c.625A>G, c.806A>G and c.879C>G) 
affecting exons 6, 7 and 9 (Table 1, Figure 1). The variant c.524A>G (pt AHO25) determines the 
amino acid change in position 175 from tyrosine to cysteine. The c.625A>G transition (pt PHP26) 
determines the substitution of the polar uncharged hydrophilic threonine in position 209 with a 
nonpolar and hydrophobic alanine residue. This amino acid is localized in the NBD-A, and is part 
of the most conserved feature of this functional domain, the phosphate-binding cassette-A (PBC-A). 
The other two novel defects affect the NBD-B and, in particular, the c.806A>G transition (pt PHP4) 
changes the negatively charged aspartic acid 269 located in the conserved N3A motif, into a 
glycine, while the c.879C>G transversion (pt PHP3) changes the aromatic hydrophobic 
phenylalanine 293 with an aliphatic hydrophobic leucine residue. In silico analysis predicted a 
pathological effect for such defects, as they cause the substitution of highly conserved amino acid 
residues located within cAMP-binding domains, and more likely affect the ability of these domains 
to sequentially bind cAMP molecules, first to NBD-B and then to NBD-A, and to trigger the 
activation of PKA catalytic subunits. 
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PRKAR1A mutation spectrum 
The updated PRKAR1A mutational spectrum comprises 18 variants (14 known and 4 novel), of 
which 16 missense and 2 nonsense (Table 2, Figure 1). 
(10-20)
 Considering the distribution of the 
mutations, exon 11 is the most affected site (52.9%), followed by exon 9 (23.5%), exon 7 (17.6%) 
and exon 8 (5.9%). No mutations were observed in other exons, acceptor-donor splice sites and 
introns.  
We confirm that PRKAR1A genetic defects are mainly private mutations. Up to now, the only 
mutational hot spot is the c.1102C>T nonsense mutation, p.(Arg368X), that, since its first 
description in 2011 by Linglart and colleagues, has been identified in 15 unrelated patients 
(Supplemental Table 3). 
(10, 11, 14, 16, 18)
 Only another mutation, c.866G>A, has been observed in two 
unrelated subjects (Supplemental Table 3). 
(14, 19)
 In addition, our analysis highlighted the presence 
of 2 amino acid residues, arginine 335 and tyrosine 373, that may be considered as putative 
mutational hot spots, being mutated in 5 unrelated patients through 5 different genetic variations 
(c.1003C>T, c.1004G>C, c.1004G>T, c.1117T>C and c.1118A>G) changing Arg to Cys/Pro/Leu 
and Tyr to His/Cys (Table 2). 
(11, 14, 16)
 These amino acids are located in highly conserved positions 
of the RIα subunit (Arg335 in the PBC-B and Tyr373, subject to phosphorylation, in an interaction 
site with PKA), thus playing a key functional role. As the association between PRKAR1A defects 
and ACRDYS represents a recent discovery, the number of recurrent mutations will likely increase 
as some mutations, affecting key amino acids, showed to recur in unrelated subjects. 
(11, 14, 16, 19) 
 
Although most of known PRKAR1A mutations alter the NBD-B (76.5%), our findings support the 
previous observation that also mutations affecting the NBD-A (23.5%) may be associated to 
ACRDYS. 
(13, 16, pt A1)
 
We also cross-referenced mutations associated to ACRDYS with those associated to Carney 
Complex and we did not find any molecular overlap, suggesting that different substitutions lead to 
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different and opposite effects on protein function, with consequent different clinical phenotypes. 
(24)
 
 
PDE4D genetic defects in our series  
The PDE4D gene codifies a class IV cAMP-specific phosphodiesterase that hydrolyzes cAMP, 
important to control specificity and temporal/spatial compartmentalization of cAMP-induced PKA 
signalling. 
(25, 26)
  
We sequenced all coding exons, from 2 to 17, of the long isoform, thus containing both Upstream 
Conserved Regions (UCRs), and we discovered 4 heterozygous missense variants (c.1279A>C, 
c.1600A>C, c.1666C>T and c.2047G>T), all novel to the literature and localized in the region 
encoding the catalytic unit (Table 1, Figure 2). Both c.1279A>C and c.1600A>C transversions 
determine the substitution of a polar uncharged hydrophilic threonine with a proline (p.(Thr427Pro) 
in pt AHO7 and p.(Thr534Pro) in pt AHO3). Proline is unique in that it is the only amino acid 
where the side chain is connected to the protein backbone twice, forming a five-membered 
nitrogen-containing ring, so that it is unable to occupy many of the main chain conformations easily 
adopted by all other amino acids. The c.1666C>T transition detected in pt AHO5 changes the polar 
histidine 556 into an aromatic, partially hydrophobic tyrosine. Finally, the c.2047G>T transversion 
causes the change of glycine 683 with a cysteine residue (pts PHP1 and PHP2). In silico analysis 
predicted a pathological effect for these PDE4D variants, as they affect highly conserved amino 
acid residues located in the catalytic domain. Moreover, in 5 patients (3 unrelated and 1 kindred), 
we found 4 new, inherited and probably benign, intronic variants (c.464+26_464+27del, 
c.501+17G>C, c.575+13T>C and c.626-24C>T) (Table 1). When available, we investigated 
patients’ RNA without finding any abnormal splicing products, and parent’s genotype, all reported 
to be clinically unaffected, determining the inheritance pattern of such previously unreported 
noncoding variants. 
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PDE4D mutation spectrum 
The PDE4D mutational spectrum now includes 25 missense variants (21 already published and 4 
found in our series) (Table 3, Figure 2). 
(11, 12, 14, 15, 17, 18, 20) 
Considering the distribution of these 
mutations, exon 5 is the most affected site (36%), followed by exon 15 (16%), exons 8 and 17 (12% 
each), exon 9 (8%) and exons 4, 6, 13 and 16  (4% each). No mutation has been observed to date in 
other exons, acceptor-donor splice sites and introns.  
According to the division into encoded protein domains, mutations are spread all along the three 
main functional domains, (44% in the UCR1, 20% in the UCR2 and 36% in the catalytic domain), 
although the region spanning the amino acid stretch 163-169, and in particular Pro164 and Phe165, 
seems to be a key functional site and a mutational hot spot, as 10 different nucleotide changes affect 
these 7 resides of the UCR1 (Table 3). 
(11, 12, 14, 15, 17, 18, 20)
 To note that also threonine in position 
526, localized in the catalytic domain, needs a careful evaluation, being affected in two ACRDYS 
patients. 
(11, 18)
  
Most of PDE4D mutations described here and elsewhere are private mutations confined to one 
patient or kindred, with the exception of 4 variants affecting the catalytic unit (c.803T>C, 
c.1586A>C, c.1835G>A and c.1850T>C), which recurred in more than one unrelated case, thus 
suggesting an underlying common molecular mechanism of formation, rather than a founder effect 
(Supplemental Table 4). 
(12, 14, 15, 17, 18)
 
 
Clinical presentation of ACRDYS patients in our series 
Clinical features of our mutated patients at diagnosis (6 males and 3 females, age ranging from 7 to 
47 years) are resumed in Table 1. All patients but one showed variable degrees of mental 
retardation, some behavior disorders and/or mild developmental delay, and all of them presented 
severe obesity. More than half of patients had resistance to hormones acting through GPCR-Gsα-
cAMP-PKA signaling pathway, in particular PTH and TSH values higher than the standard. Typical 
clinical and/or x-ray features of brachydactyly and severe short stature were reported in 6 subjects. 
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Facial dysmorphisms such as rounded face were observed in 5 mutated patients. It is to note that 
after obtaining the molecular results, these patients were re-evaluated and a slight flattening of nasal 
bridge was recorded. As additional features, 3 patients showed IUGR and neonatal hypoglycemia, 
while other clinical characteristics associated only to single patients are resumed in Table 1. Of 
note, patient PHP26 also manifested subcutaneous ossifications at her right leg soon. At clinical 
examination, before molecular analysis, no apparent differences in the skeletal phenotype were 
noted that could help differentiate patients carrying PRKAR1A and PDE4D mutations.  
Considering our series according to the affected gene, PTH resistance was diagnosed in 3 of 4 
PRKAR1A-mutated patients (pts PHP3, PHP4 and PHP26) and 3 of them (pts PHP4, PHP26 and 
AHO25) displayed also TSH resistance. Patients PHP3, PHP4 and AHO26 also showed short 
stature and mild mental retardation/developmental delay, while patients PHP4, PHP26 and AHO25 
had brachydactyly and obesity.  
As for PDE4D-mutated patients, only siblings PHP1 and PHP2 showed elevated PTH and TSH 
levels due to hormone resistance, while patient AHO7 had resistance to TSH. All subjects presented 
with variable degrees of mental retardation and developmental delay, and were obese. Only 3 of 5 
demonstrated short stature. To note that they were affected by severe brachydactyly, with the 
exception of patients PHP1 and PHP2, while only patients AHO3 and AHO5 showed a typical 
facial dysostosis.  
 
Clinical features associated to ACRDYS 
We next considered the clinical presentation of all ACRDYS patients, both our cases and those 
previously reported in the literature, with the aim of pointing out differences between phenotypes 
associated with PRKAR1A and PDE4D mutations, and to identify specific clinical features 
associated to ACRDYS deserving surveillance during follow-up (Supplemental Tables 3 and 4).  
Our investigation confirmed that the phenotype resulting from PRKAR1A defects is frequently 
associated with multihormone resistance (rPTH= 76%, rTSH= 73% and rPTH+TSH= 64%), while 
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in case of PDE4D mutation resistance to PTH or TSH is present only in a small subset of patients 
(rPTH= 27%, rTSH= 8% and rPTH+TSH= 5%). An altered response to FSH was reported in about 
18% of PRKAR1A-mutated patients, and cryptorchidism and/or lack of pubertal spurt, possibly 
secondary to hormone resistance, were described in about 19% of patients with PDE4D mutations.  
Overall, the most frequent clinical features were brachydactyly (PRKAR1A= 97% and PDE4D= 
92%) and dysmorphic facies (PRKAR1A= 75% and PDE4D= 90%). Obesity and advanced bone age 
were reported in less than half of the cases, with no apparent differences between the two ACRDYS 
subtypes. Phenotypic characteristics which appeared to have different frequencies according to the 
mutated gene were short stature (PRKAR1A= 94% and PDE4D= 57%), cone-shaped epiphyses 
(PRKAR1A=72% and PDE4D=16%) and mental/behavioural defects (PRKAR1A=48% and 
PDE4D=95%). These values could be underestimated, as different research groups focused their 
attention on different clinical aspects, suggesting the need to harmonize clinical protocols and to 
deeply evaluate the endocrine status in all patients, independently of the mutated gene.  
Finally, in a subset of patients we recorded additional recurring comorbidities that deserve further 
investigation in larger cohorts in order to define their possible relationship with ACRDYS. In 
particular, 6% of patients with PRKAR1A defects showed hearing loss and 15% IUGR, while about 
8% of patients with PDE4D defects were affected by hearing loss, recurrent otitis media, 
intracranial hypertension, shypo-deformity of knees and shoulders and atopy/rhinitis/eczema.  
For both genes, we did not observe significant gender difference (% mutated females vs males: 
PRKAR1A=55% vs 45%, PDE4D= 41% vs 59%), not even in the presentation of specific signs, 
including PTH and/or multihormone resistance, facial dysmorphic features, brachydactyly, short 
stature, obesity and the age at diagnosis. Notably, male patients bearing PRKAR1A mutations (11 of 
15 reported cases) showed an increased frequency of intellectual disabilities and/or behavioural 
problems respect to mutated females (5 of 18 cases). However, due to the recent discovery of 
ACRDYS genetic defects, these data should not be considered as conclusive, deriving from the 
analysis of a small series (PRKAR1A n=33 and PDE4D n=37). 
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Discussion 
Gsα-cAMP signaling-linked disorders demonstrated a substantial overlap from the clinical point of 
view, and it is still difficult to make a conclusive diagnosis without a molecular confirmation of the 
underlying genetic defect.  This paper presents our data obtained through the screening of genetic 
variants at PRKAR1A/PDE4D genes in a series of patients with an initial clinical diagnosis of 
PHP1A/AHO but negative for GNAS defects.  
Although we did not perform functional studies to confirm the pathological effect of PRKAR1A 
and PDE4D genetic variants found in our cases, conservation and in silico analysis prompt their 
causative role in the development of the clinical phenotype. Our findings are further supported by 
previous studies demonstrating that PRKAR1A mutations discovered in patients cause a defect in 
PKA activation by cAMP, associated with a decreased responsiveness of PKA to cAMP, and their 
dominant negative effect on PKA function. 
(10, 13)
 Recently, Kaname and colleagues performed 
functional studies to analyze PDE4D mutants and generated Pde4d knockout rats, demonstrating 
that PDE4D loss results in the skeletal dysplasia phenotype observed in Acrodysostosis. 
(18)
 
Meanwhile,  the functional consequences of the PDE4D coding changes was also confirmed in 
zebrafish, suggesting  a dominant negative effect. 
(17)
Moreover, 10 patients belonging to 4 families 
with 4 different PDE4D mutations (including the kindred described in the present paper) have 
been reported, confirming the co-segregation of these molecular defects with the disorder 
(Supplemental Table 4). 
(15, 18, pts P1/P2)
 Interestingly, structural variants of chromosome 5q12.1 
determining haploinsufficiency of PDE4D resulted in a novel intellectual disability syndrome, but 
several opposing features compared with Acrodysostosis (characteristic faces with prominent nasal 
bridge and maxillary hyperplasia, low BMI, long extremities and fingers). 
(17)
 
The review of published mutations associated to ACRDYS (summarized in Tables 2 and 3) 
demonstrated that PRKAR1A/PDE4D genetic variants may affect different functional domains and 
are mainly private mutations. Only few variants recurred in more than one unrelated case but, since 
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ACRDYS-associated genes have been recently discovered, the number of recurrent mutations is 
likely to increase. 
Previous reports documented the phenotypic similarities and differences associated with PRKAR1A 
and PDE4D mutations causing ACRDYS, and identified two subtypes of this entity: type 1 
(ACRDYS1 - MIM101800), with hormonal resistance and resulting from PRKAR1A defects, and 
type 2 (ACRDYS2 - MIM614613), resulting from PDE4D defects. 
(21)
 Typical skeletal and facial 
dysmorphisms characterizing these subtypes are quite similar, possibly more severe when the 
PDE4D gene is affected, and comprise: broad face, widely spaced eyes, maxillonasal hypoplasia, 
small hands/feet affected by brachydactyly type E (BDE), severe short stature, cone-shaped 
epiphyses with early epiphyseal fusion and advanced bone age. Bone growth is regulated by the 
PTHrp/PTH receptor type 1 (PTH1R) activation that stimulates slow chondrocyte differentiation 
into hypertrophic cells, thus it was proposed that skeletal abnormalities derive from a general 
impairment of the cAMP/PKA pathway. 
(14)
 Conversely, other clinical features seem to be more 
frequently associated with a specific subgroup, like intrauterine growth restriction and hormonal 
resistance in PRKAR1A mutated patients and mental retardation in patients with PDE4D defects. 
Although both genes are involved in the GPCR-Gsα-cAMP-PKA pathway, PRKAR1A ubiquitous 
expression compared to PDE4D isoforms tissue-specific distribution may account for these 
observed phenotypic differences.  
Clinical data collected in our cohort of ACRDYS patients confirmed an elevated phenotypic 
heterogeneity, both in PRKAR1A and PDE4D mutated patients, and no apparent differences in 
skeletal phenotype that could help distinguish patients before genotyping were noted (Table 1). 
Afterwards, we analysed all ACRDYS patients, both our cases and previously reported in the 
literature, to find phenotypic differences between PRKAR1A and PDE4D mutated patients and 
specific clinical features associated to ACRDYS, deserving a careful surveillance during follow-up 
(Supplemental Tables 3 and 4).  
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Considering our subjects affected by PRKAR1A mutations, 3 of them were initially diagnosed as 
having PHP1A because of the presence of PTH resistance and AHO signs, while the other one as 
possibly affected by AHO. The detection of PRKAR1A mutations in these latter patients further 
supports the hypothesis that also defects in the NBA-A domain can impair PKA RIα activity. (13, 16) 
As for PDE4D-mutated patients, multihormone resistance was observed only in the kindred 
PHP1&2 (elevated PTH and TSH levels), while 2 patients showed a resistance limited to TSH. So, 
as expected, resistance to PTH and/or TSH is mainly related to PRKAR1A defects, but endocrine 
disorders signaling cannot be completely excluded in the presence of PDE4D defects so that 
patients should be carefully screened also for an altered response to hormones acting through 
GPCRs. Moreover, since 16% of all PDE4D-mutated patients were affected by cryptorchidism 
and/or lack of pubertal spurt, it would be worthwhile investigating whether these signs are 
secondary to hormone deficiency or resistance. Finally, there is no evident explanation as to why 
PRAKAR1A/PDE4D mutated patients exhibit hormone resistances similar to those observed in 
GNAS-mutated subjects, despite no tissue-specific imprinting has been demonstrated for ACRDYS-
related genes. No apparent differences between ACRDYS subtypes were found in terms of frequent 
clinical features, such as brachydactyly, obesity and advanced bone age. Other phenotypic 
characteristics (short stature, cone-shaped epiphyses, mental/behavioural defects) seemed to have 
different frequencies according to the mutated gene, and a subset of patients presented additional 
comorbidities (hearing loss, IUGR, recurrent otitis media, intracranial hypertension and atopy). 
Further studies, involving larger series of patients and aimed to investigate specific clinical features, 
are needed to obtain conclusive data.  
In conclusion, the present study reports 8 novel mutations in PRKAR1A and PDE4D coding exons 
associated with ACRDYS, discovered in 9 patients who were previously diagnosed as having 
PHP/AHO, further expanding the spectrum of mutations  and underlining the importance of 
identifying such genetic alterations for both diagnostic and research purposes.   Furthermore, thanks 
to the review of all published mutations associated to ACRDYS, the present work provides an 
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updated compilation of mutational and phenotypic data.  Overall, the molecular and clinical overlap 
among these Gsα-cAMP signaling-linked disorders indicates the need for different classification 
models and for a deeper investigation of the mechanisms through which defects of the cAMP 
signaling cascade cause either common or specific clinical phenotypes, in order to elaborate  
patient-specific algorithms . 
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Figure Legends 
Figure 1: Novel PRKAR1A mutations associated to ACRDYS. The upper part shows the 
PRKAR1A structure (protein domains and gDNA) and the genomic location of previously detected 
mutations in ACRDYS patients (dots over exons). At the bottom, the electropherograms of 
missense mutations found in our series are compared with wild-type reference sequences. 
Figure 2: Novel PDE4D mutations associated to ACRDYS. The upper part shows the PDE4D 
structure (protein domains and gDNA) and the genomic location of previously detected mutations 
in ACRDYS patients (dots over exons). At the bottom, the electropherograms of missense 
mutations found in our series are compared with wild-type reference sequences. 
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Tables 
Table 1: Clinical and molecular characteristics of patients with PRKAR1A and PDE4D novel genetic defects described in the present study.     
pt ID sex age PTH TSH Ca P SS Ob RF Br HO BD/MR additional features gene 
exon 
intron 
genetic change 
aminoacid 
change 
inheritance 
missense variants novel to the literature 
PHP1 F 7y ↑ ↑ ↔ ↔   X       X 
familial case (twins), 
craniosynostosis 
PDE4D 17 c.2047G>T p.(Gly683Cys) fam 
PHP2 M 7y ↑ ↑ ↔   ↔   X       X 
familial case (twins), 
craniosynostosis 
PDE4D 17 c.2047G>T p.(Gly683Cys) fam 
PHP3 M 10y 73 4.07 10 6.2 X X X     X 
IUGR, neonatal 
hypoglycemia, 
gastroesophageal 
reflux, dysmorphic 
spines, hrGH 4-8th 
years  
PRKAR1A 9 c.879C>G p.(Phe293Leu) de novo 
PHP4 M 32y 94 6 9.6 4.6 X X X X   X 
IUGR, neonatal 
hypoglycemia, 
enamel dysplasia  
PRKAR1A 9 c.806A>G p.(Asp269Gly) de novo 
PHP26 F 11.5y 129 9.6 9.6 5.7   X X X X   
IUGR, caeliac 
disease, glucose 
intolerance with 
insulin resistance, 
severe peripheral 
dysostosis, cone 
shaped-epiphyses, 
progressive growth 
failure, lack of 
pubertal spurt 
PRKAR1A 7 c.625A>G p.(Thr209Ala) de novo 
AHO3 M 13y 25.4 1.5 10.1 5.4 X X X X   X None until now PDE4D 15 c.1600A>C p.(Thr534Pro) n.a. 
 This article is protected by copyright. All rights reserved 22 
AHO5 M 29y 6 2.8 9.5 4.6 X X X X   X 
cryptorchidism, 
vesicoureteral reflux  
PDE4D 16 c.1666C>T p.(Hys556Tyr) de novo 
AHO7 F 47y 27 7.8  9.7 4.9  X X   X   X cholelithiasis PDE4D 13 c.1279A>C p.(Thr427Pro) n.a. 
AHO25 M 11y 34.8 10.94 9.5 5.2 X X   X   X hypospadias PRKAR1A 6 c.524A>G p.(Tyr175Cys) n.a. 
intronic variants novel to the literature 
AHO6 F 9y 10.6 7.99 9.8 5.6   X X X   X 
cholelithiasis, 
hypoadrenalism 
PDE4D 4i c.464X26_464X27del p.(?) mat 
AHO1 F 2y 22 8.3 9.9  5.5              
familial case, 
osteoporisis 
PDE4D 5i c.501X17G>C p.(?) fam 
AHO2 F 5y 42 6 10 5.2 X X   X     
familial case, IUGR, 
gastroesophageal 
reflux,bilateral 
sensorineural 
hearing loss,shypo-
deformity of knees 
PDE4D 5i c.501X17G>C p.(?) fam 
AHO22 F 15y 41 3.92 9.9 3.9 X X X X   X 
Arnold Chiari 
Malformation, 
neonatal 
hypoglycemia, 
nocturnal enuresis, 
convergent 
strabismus, bilatral 
madelung deformity 
PDE4D 6i c.575X13T>C p.(?) n.a. 
AHO4 F 19y 22 2.5 2.4 4.2   X X X   X 
PCOS, hirsutism, 
menstrual 
irregularities, genu 
valgum  
PDE4D 7i c.626-24C>T p.(?) mat 
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Legend Pt ID: patient identifier number; F: female, M: male; age: age at molecular diagnosis (years); PTH: PTH level (10-65 pg/ml); TSH: TSH level 
(0.27-4.2 µU/ml); Ca: calcaemia (9.5-11 mg/dl); P: phosphatemia (4-5.7 mg/dl); values outside reference values are highlighted in bold; SS: short 
stature; ↑: value above normal range; ↔: value within normal range; Ob: obesity; RF: round facies; Br: brachydactyly; HO: heterotopic ossification; 
BD/MR: behavioural disorders and/or mental retardation; PCOS: polycystic ovary syndrome; i: intron; c.: nucleotide position of the variant 
according to the translation start site; p.: position of the aminoacid change according; fam: familial (affected siblings, no parents testing); mat: 
maternal inheritance; n.a.: not available for testing. 
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Table 2: Table summarizing all novel and reported in the literature PRKAR1A mutations associated 
to ACRDYS. 
 
exon genetic change aminoacid change protein domain Reference 
6 c.524A>G p.(Tyr175Cys) NBD-A our series 
7 c.625A>G p.(Thr209Ala) PBC of the NBD-A our series 
7 c.637G>A p.(Ala213Thr) PBC of the NBD-A Muhn et al. 2013 
7 c.679G>A p.(Asp227Asn) NBD-A Muhn et al. 2013 
8 c.715A>G p.(Thr239Ala) NBD-A Nagasaki et al. 2012 
9 c.806A>G p.(Asp269Gly) NBD-B - N3A motif our series 
9 c.854A>G p.(Gln285Arg) NBD-B - interaction with PKA Linglart et al. 2012 
9 c.866G>A p.(Gly289Glu) NBD-B Linglart et al. 2012/ Li et al. 2014 
9 c.879C>G p.(Phe293Leu) NBD-B our series 
11 c.980T>C p.(Ile327Thr) PBC of the NBD-B Lee et al. 2012 
11 c.983C>T p.(Ala328Val) PBC of the NBD-B Linglart et al. 2012 
11 c.1003C>T p.(Arg335Cys) PBC of the NBD-B Muhn et al. 2013 
11 c.1004G>C p.(Arg335Pro) PBC of the NBD-B Lee et al. 2012 
11 c.1004G>T p.(Arg335Leu) PBC of the NBD-B Linglart et al. 2012 
11 c.1102C>T p.(Arg368X) NBD-B - interaction with 263 residue Linglart et al. 2011/Muhn et al. 2013/Kaname et al. 2014 
11 c.1114C>T p.(Gln372X) NBD-B Linglart et al. 2012 
11 c.1117T>C p.(Tyr373His) NBD-B - interaction with PKA Michot et al. 2012 
11 c.1118A>G p.(Tyr373Cys) NBD-B - interaction with PKA Muhn et al. 2013 
Legend PBC: phosphate-binding cassette; NBD: nucleotide binding domain; PKA: protein kinase A. Novel mutations are highlighted in bold 
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Table 3: Table summarizing all novel and reported in the literature PDE4D mutations associated to 
ACRDYS. 
exon 
genetic change 
NM_001165899/NM_001104631 
aminoacid change 
NM_001165899/NM_001104631 
protein 
domain 
Reference 
4 c.385T>G/ c.568T>G p.(Ser129Ala)/ p.(Ser190Ala) 
UCR1, PKA 
consensus 
(PKA-
phosphorilated 
Ser) 
Michot et al. 2012 
5 c.488C>T/ c.671C>T p.(Thr163Ile)/ p.(Thr224Ile) UCR1 Mitsui et al. 2014 
5 c.490C>A/ c.673C>A p.(Pro164Thr)/ p.(Pro225Thr) UCR1 Michot et al. 2012 
5 c.491C>T/ c.674C>T p.(Pro164Leu)/ p.(Pro225Leu) UCR1 Lynch et al. 2012 
5 c.493T>G/ c.676T>G p.(Phe165Val)/ p.(Phe226Val) UCR1 Lindstrand et al. 2014 
5 c.494T>C/ c.677T>C p.(Phe165Ser)/ p.(Phe226Ser) UCR1 Michot et al. 2012 
5 c.494T>G/ c.677T>G p.(Phe165Cys)/ p.(Phe226Cys) UCR1 Lindstrand et al. 2014 
5 c.496G>T/ c.679G>T p.(Ala166Ser)/ p.(Ala227Ser) UCR1 Linglart et al. 2012 
5 c.499C>G/ c.682C>G p.(Gln167Glu)/ p.(Gln228Glu) UCR1 Lee et al. 2012 
5 c.500A>C/ c.683A>C p.(Gln168Pro)/ p.(Gln228Pro) UCR1 Kaname et al. 2014 
6 c.506T>C/ c.689T>C p.(Leu169Ser)/ p.(Leu230Ser) UCR1 Kaname et al. 2014 
8 c.719G>C/ c.902G>C p.(Ser240Thr)/ p.(Ser301Thr) UCR2 Lynch et al. 2012 
8 c.724A>G/ c.907A>G p.(Met242Val)/ p.(Met303Val) UCR2 Lindstrand et al. 2014 
8 c.728C>T/ c.911C>T p.(Ala243Val)/ p.(Ala304Val) UCR2 Lynch et al. 2012 
9 c.803T>C/ c.986T>C p.(Val268Ala)/ p.(Val329Ala) UCR2 Lynch et al. 2012/Lindstrand et al. 2014 
9 c.815T>C/ c.998T>C p.(Ile272Thr)/ p.(Ile333Thr) UCR2 Mitsui et al. 2014 
13 c.1279A>C/ c.1462A>C p.(Thr427Pro)/ p.(Thr488Pro) Catalitic unit our series 
15 c.1576A>C/ c.1759A>C p.(Thr526Pro)/ p.(Thr587Pro) Catalitic unit Michot et al. 2012 
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15 c.1576A>G/ c.1759A>G p.(Thr526Ala)/ p.(Thr587Ala) Catalitic unit Kaname et al. 2014 
15 c.1586A>C/ c.1769A>C p.(Glu529Ala)/ p.(Glu590Ala) Catalitic unit Linglart et al. 2012/Lee et al. 2012 
15 c.1600A>C/ c.1783A>C p.(Thr534Pro)/ p.(Thr595Pro) Catalitic unit our series 
16 c.1666C>T/ c.1849C>T p.(Hys556Tyr)/ p.(Hys617Tyr) Catalitic unit our series 
17 c.1835G>A/ c.2018G>A p.(Gly612Asp)/ p.(Gly673Asp) Catalitic unit Lee et al. 2012/Kaname et al. 2014 
17 c.1850T>C/ c.2033T>C p.(Ile617Thr)/ p.(Ile678Thr) Catalitic unit Lynch et al. 2012/Lindstrand et al. 2014/Kaname et al. 2014 
17 c.2047G>T/ c.2230G>T p.(Gly683Cys)/ p.(Gly744Cys) Catalitic unit our series 
Legend UCR: upstream conserved region; PKA: protein kinase A. Novel mutations are highlighted in bold 
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